Eric Winzer, CFO
OpGen Incorporated is a privately owned company, founded in 2002 by the Wisconsin Alumni Research Foundation (WARF) as a Delaware corporation. Current investors include CHL Medical Partners, Harris & Harris Group, Versant Ventures, Mason Wells, Cross Creek Advisors, In-Q-Tel and jVEN Capital LLC.
Please see the OpGen company overview for description of OpGen technologies and markets.
Versant Ventures consists of a seasoned team of twelve managing directors collectively possess more than 130 years of venture capital investing experience and more than 150 years of operating experience. Versant is committed to transforming healthcare through innovation, and invests in all segments of healthcare including, medical devices, life sciences, healthcare services and healthcare information technology. These companies must have highly differentiated products or services that represent substantial innovation over existing practices. While these investments are typically primarily in early stage companies, Versant has and will occasionally invest in later stage companies with the right attributes. www.versantventures.com
jVEN Capital, LLC is a venture capital and investment management company focused on the Life Sciences. The company is active in the areas of personalized medicine, genetics, medical devices, and specialty therapeutics. Established in 2007 by Evan Jones, a successful entrepreneur in the molecular diagnostics field, jVEN Capital works closely with its portfolio companies to help develop their visions into substantial businesses to meet unmet medical needs. Current investments include OpGen Inc., Signature Genomic Laboratories, LLC, Veracyte Inc, and CAS Medical Systems Inc.
CHL Medical Partners is a leading venture capital firm focused on partnering with entrepreneurs and inventors in creating and financing innovative seed and early-stage companies in the biotechnology, molecular diagnostics, healthcare services and medical device sectors. The five partners of CHL Medical Partners have an average of 18 years of investment experience devoted to the founding and nurturing of life science companies. Our team is well-known among industry observers and life science investment professionals for identifying and validating visionary scientific and healthcare ideas and creating business with extraordinary market potential. Collectively, we have invested in and grown more than 80 start ups, establishing a notable track record of building prominent companies with products and services that significantly improve patient care. With committed capital of more than $300 million, we are continually reviewing promising translational medical research and innovative healthcare service models for the next high-value, pioneering investment opportunities. www.chlmedical.com
Harris & Harris Group (Nasdaq: TINY) is a publicly traded venture capital firm based in New York City, NY and Palo Alto, CA. It has been making venture capital investments for over 30 years. Harris & Harris Group builds transformative companies from disruptive science and leverages its core scientific expertise to identify new technology trends, to access high quality science and intellectual property, and to invest in early-stage businesses. Its team has the unique ability to identify and diligence the network of discoveries that come from understanding science at the intersection of different scientific disciplines with biology as a focus. Harris & Harris Group refers to this thesis as BIOLOGY+. The BIOLOGY+ investment thesis places Harris & Harris Group at the center of the discoveries impacting some of the most important life science challenges of the future.
Cross Creek Advisors was founded in 2006 inside of Wasatch Advisors, Inc. as a venture manager investing in late-stage venture companies. Cross Creek leverages its unique public markets expertise, venture fund relationships and late stage venture focus to help companies successfully transition from the private to public markets. www.CrossCreekAdvisors.com
Mason Wells is a highly experienced and one of the leading private equity investors in the Midwestern United States. Founded in 1982 as a subsidiary of Marshall & Ilsley Corporation, Mason Wells became an independent firm in 1998. Since 1982, we have invested in three specific industry sectors: engineered products and services (including biomedical); outsourced business services (including healthcare); and specialty paper and packaging. The two key aspects of every transaction that we focus on are the management team and opportunities to build and improve a business. We work in partnerships with experienced, entrepreneurial management teams to implement our disciplined and proven Value Creation System to create long term sustainable value in companies. www.masonwells.com
In-Q-Tel identifies and partners with companies developing cutting-edge technologies to help deliver these solutions to the Central Intelligence Agency and the broader U.S. Intelligence Community (IC) to further their missions. To best serve its customers, In-Q-Tel plays multiple roles: a technology accelerator, fostering development and introduction of technologies needed by the Intelligence Community; a capabilities builder, helping nascent commercial technologies mature into commercial-off-the-shelf (COTS) products the government can buy; an idea lab and forum for innovation, providing the Intelligence Community with insight and access to both new technologies and leading innovators and thinkers; and a strategic investment firm, investing in companies and helping build businesses into reliable providers for the Intelligence Community. http://www.iqt.org/